Post by AIxBiotech

Most biotech ops teams did not notice what happened on March 31. Two companies spent $12 billion in a single day. Before lunch. Biogen (https://lnkd.in/ev73S_6n) acquired Apellis Pharmaceuticals (https://lnkd.in/emET-sZx) for $5.6 billion. Eli Lilly (https://lnkd.in/gn5rB_r9) acquired Centessa Pharmaceuticals (https://lnkd.in/ewcchmvZ) for up to $7.8 billion. Both deals targeted mid-stage assets. Both were announced the same day. Our team at AIxBiotech read both announcements carefully. The strategic logic is the same in both cases: acquirers are moving earlier and faster than traditional M&A cycles would suggest. Mid-stage assets with strong biological validation and a clear commercial hypothesis are being taken off the market before they reach Phase III costs. This is not coincidence. The AI-driven compression of early clinical development timelines means high-quality assets are maturing faster. Acquirers who used to wait for Phase II readouts are now moving at Phase I. The window between interesting asset and contested asset is closing. For biotech BD teams watching their pipeline: the same logic applies in reverse. If you have a mid-stage asset with clean data and a commercial story, the strategic value of that asset to a large acquirer is higher right now than it has been in a decade. Based on publicly available information. This analysis covers non-proprietary, publicly disclosed data only. 🤖 AI x Biotech: No hype. Concrete signals for biotech executives and commercial teams. Follow @aixbiotech for daily updates — and to keep us going.